Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 24, Issue 3, 2009, Pages 990-996

  Reuter, Stephanie E ^a   Faull, Randall J ^b   Ranieri, Enzo ^c   Evans, Allan M ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

Acylcarnitine; Anaemia; Erythropoietin; Haemodialysis; L carnitine

Indexed keywords

ACYLCARNITINE; CARNITINE; ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; FEMALE; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECOMMENDED DRUG DOSE;

ADULT; AGED; ANEMIA; CARNITINE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 60749128107     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn588     Document Type: Article

References (49)

1. Golper TA, Goral S, Becker BN et al. l-carnitine treatment of anemia. Am J Kidney Dis 2003; 41(Suppl 4): S27-S34
2. Adamson JW, Eschbach JW. Management of the anaemia of chronic renal failure with recombinant erythropoietin. Q J Med 1989; 73: 1093-1101
3. Drueke TB. R-HuEPO hyporesponsiveness - who and why? Nephrol Dial Transplant 1995; 10(Suppl 2): 62-68
4. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000
5. Wolcott DL, Marsh JT, La Rue A et al. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 1989; 14: 478-485
6. Zhang Y, Thamer M, Stefanik K et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876
7. Berns JS, Mosenkis A. Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis. Hemodial Int 2005; 9: 7-22
8. Bommer J. Saving erythropoietin by administering L-carnitine? Nephrol Dial Transplant 1999; 14: 2819-2821
9. Hörl WH. Is there a role for adjuvant therapy in patients being treated with epoetin? Nephrol Dial Transplant 1999; 14(Suppl 2): 50-60
10. Hörl WH. Adjunctive therapy in anaemia management. Nephrol Dial Transplant 2002; 17(Suppl 5): 56-59
11. Reuter SE, Evans AM, Faull RJ et al. Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in endstage renal disease. Ann Clin Biochem 2005; 42: 387-393
12. Albertazzi A, Capelli P, Di Paolo B et al. Endocrine-metabolic effects of L-carnitine in patients on regular dialysis treatment. Proc Eur Dial Transplant Assoc 1983; 19: 302-307
13. Bérard E, Iordache A. Effect of low doses of L-carnitine on the response to recombinant human erythropoietin in hemodialyzed children: about two cases. Nephron 1992; 62: 368-369
14. Boran M, Dalva I, Gonenc F et al. Response to recombinant human erythropoietin (r-HuEPO) and L-carnitine combination in patients with anemia of end-stage renal disease. Nephron 1996; 73: 314-315
15. Caruso U, Leone L, Cravotto E et al. Effects of L-carnitine on anemia in aged hemodialysis patients treated with recombinant human erythropoietin: a pilot study. Dial Transplant 1998; 27: 498-506
16. Donatelli M, Terrizzi C, Zummo G et al. Effects of L-carnitine on chronic anemia and erythrocyte adenosine triphosphate concentration in hemodialyzed patients. Curr Ther Res Clin Exp 1987; 41: 620-624
17. Kavadias D, Fourtounas C, Tsouchnikas J et al. L-carnitine and erythropoietin requirements in hemodialysis patients. Am J Kidney Dis 1996; 28: 156
18. Kletzmayr J, Mayer G, Legenstein E et al. Anemia and carnitine supplementation in hemodialyzed patients. Kidney Int 1999; 55(Suppl 69): S93-S106
19. Labonia WD. L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 1995; 26: 757-764
20. Labonia WD, Morelli OH Jr, Gimenez MI et al. Effects of L-carnitine on sodium transport in erythrocytes from dialyzed uremic patients. Kidney Int 1987; 32: 754-759
21. Matsumoto Y, Amano I, Hirose S et al. Effects of L-carnitine supplementation on renal anemia in poor responders to erythropoietin. Blood Purif 2001; 19: 24-32
22. Romagnoli GF, Naso A, Carraro G et al. Beneficial effects of L-carnitine in dialysis patients with impaired left ventricular function: an observational study. Curr Med Res Opin 2002; 18: 172-175
23. Sotirakopoulos N, Athanasiou G, Tsitsios T et al. Effect of L-carnitine supplementation on red blood cells deformability in hemodialysis patients. Ren Fail 2000; 22: 73-80
24. Trovato GM, Carpinteri G, Catalano D et al. Body composition and long-term levo-carnitine supplementation. Clin Ter 1998; 149: 209-214
25. Trovato GM, Ginardi V, Di Marco V et al. Long-term L-carnitine treatment of chronic anaemia of patients with end-stage renal disease. Curr Ther Res Clin Exp 1982; 31: 1042-1049
26. Veselá E, Racek J, Trefil L et al. Effect of L-carnitine supplementation in hemodialysis patients. Nephron 2001; 88: 218-223
27. Hurot JM, Cucherat M, Haugh M et al. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002; 13: 708-714
28. Eknoyan G, Latos DL, Lindberg J. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis 2003; 41: 868-876
29. Reuter SE, Evans AM, Chace DH et al. Determination of the reference range of endogenous plasma carnitines in healthy adults. Ann Clin Biochem 2008; 45: 585-592
30. Evans AM, Faull RJ, Nation RL et al. Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease. Kidney Int 2004; 66: 1527-1534
31. Reuter SE, Faull RJ, Evans AM. L-carnitine supplementation in the dialysis population - are Australian patients missing out? Nephrology 2007; 13: 3-16
32. Golper TA, Wolfson M, Ahmad S et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Kidney Int 1990; 38: 904-911
33. Rodriguez-Segade S, Alonso de la Pena C, Paz JM et al. Carnitine deficiency in haemodialysed patients. Clin Chim Acta 1986; 159: 249-256
34. Rodriguez-Segade S, Alonso de la Pena C, Paz M et al. Carnitine concentrations in dialysed and undialysed patients with chronic renal insufficiency. Ann Clin Biochem 1986; 23(Part 6): 671-675
35. Wanner C, Förstner-Wanner S, Schaeffer G et al. Serum free carnitine, carnitine esters and lipids in patients on peritoneal dialysis and hemodialysis. Am J Nephrol 1986; 6: 206-211
36. Wanner C, Riegel W, Schaefer RM et al. Carnitine and carnitine esters in acute renal failure. Nephrol Dial Transplant 1989; 4: 951-956
37. Wanner C, Wäckerle B, Boeckle H et al. Plasma and red blood cell carnitine and carnitine esters during L-carnitine therapy in hemodialysis patients. Am J Clin Nutr 1990; 51: 407-410
38. Alhomida AS, Duhaiman AS, Al-Jafari AA et al. Serum total, free and acyl carnitine concentrations in chronic glomerulonephritis patients. Med Sci Res 1996; 24: 495-498
39. Matsumura M, Hatakeyama S, Koni I et al. Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients. Nephron 1996; 72: 574-578
40. Kooistra MP, Struyvenberg A, van Es A. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels. Nephron 1991; 57: 127-128
41. Kobayashi A, Watanabe H, Fujisawa S et al. Effects of L-carnitine and palmitoylcarnitine on membrane fluidity of human erythrocytes. Biochim Biophys Acta 1989; 986: 83-88
42. Scholte HR, Luyt-Houwen IE, Vaandrager-Verduin MH. The role of the carnitine system in myocardial fatty acid oxidation: carnitine deficiency, failing mitochondria and cardiomyopathy. Basic Res Cardiol 1987; 82(Suppl 1): 63-73
43. De Los Reyes B, Navarro JA, Perez-Garcia R et al. Effects of L-carnitine on erythrocyte acyl-CoA, free CoA, and glycerophospholipid acyltransferase in uremia. Am J Clin Nutr 1998; 67: 386-390
44. De Los Reyes B, Perez-Garcia R, Liras A et al. L-carnitine normalizes the reduced carnitine palmitoyl transferase activity in red cells from haemodialysis patients. Nephrol Dial Transplant 1997; 12: 1300-1301
45. Yoon HR, Hong YM, Boriack RL et al. Effect of L-carnitine supplementation on cardiac carnitine palmitoyltransferase activities and plasma carnitine concentrations in adriamycin-treated rats. Pediatr Res 2003; 53: 788-792
46. Cho KS, Proulx P. Lysis of erythrocytes by long-chain acyl esters of carnitine. Biochim Biophys Acta 1969; 193: 30-35
47. Cho KS, Proulx P. Studies on themechanism of hemolysis by acyl carnitines, lysolecithins and acyl cholines. Biochim Biophys Acta 1971; 225: 214-223
48. Cho KS, Proulx P. Interactions of acyl carnitines and other lysins with erythrocytes and reconstituted erythrocyte lipoproteins. Biochim Biophys Acta 1973; 318: 50-60
49. Evans AM, Faull R, Fornasini G et al. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. Clin Pharmacol Ther 2000; 68: 238-249